Prognostic value of the revised International Prognostic Scoring System five-group cytogenetic abnormality classification for the outcome prediction of hematopoietic stem cell transplantation in pediatric myelodysplastic syndrome
- 10 September 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Bone Marrow Transplantation
- Vol. 56 (12), 3016-3023
- https://doi.org/10.1038/s41409-021-01446-z
Abstract
Cytogenetic abnormalities are a major risk factor for relapse after hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS). We aimed to evaluate the value of the five-group cytogenetic classification according to the revised International Prognostic Scoring System (R-IPSS) for predicting the outcome after HSCT in pediatric patients with MDS. We retrospectively analyzed the Japanese registration data of 242 pediatric patients with MDS. According to the R-IPSS classification, 112 (45.5%) patients had good, 55 (22.7%) had intermediate, 64 (26.4%) had poor, and 11 (4.6%) had very poor cytogenetics. The 5-year overall survival (5yOS) was 72%, 69%, 59%, and 30% in the good, intermediate, poor, and very poor cytogenetic subgroups (p = 0.026), respectively. The very good, good, and intermediate subgroups were grouped into a “standard” subgroup and reclassified into three subgroups (standard, poor, and very poor). Patients with very poor risk had worse 5yOS (hazard ratio 2.17, 95% confidence interval (CI) 1.02–4.61; p = 0.04) and a much higher 5yCIR (hazard ratio 2.52, 95% CI 1.05–6.04; p = 0.04) than those of patients in the standard group in the multivariate analysis, indicating that very poor risk cytogenetic characteristics independently predicted worse outcome after HSCT in pediatric patients with MDS.Keywords
This publication has 32 references indexed in Scilit:
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsThe New England Journal of Medicine, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesThe New England Journal of Medicine, 2011
- Allogeneic hematopoetic stem cell transplantation in pediatric myelodysplastic syndromes: Improved outcomes for de novo diseasePediatric Transplantation, 2011
- Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 studyLeukemia, 2011
- Analysis of risk factors influencing outcome in children with myelodysplastic syndrome after unrelated cord blood transplantationLeukemia, 2010
- Reduced-Intensity Conditioning Regimen Workshop: Defining the Dose Spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant ResearchTransplantation and Cellular Therapy, 2009
- Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic TransplantationTransplantation and Cellular Therapy, 2007
- Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP systemInternational Journal of Hematology, 2007
- Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndromeBlood, 2002